Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Infectious Disease · Latent Tuberculosis Infection

Treatment Options for Latent TB Infection

At a Glance

Latent TB infection is treated with modern short-course regimens, such as 3HP or 4R, lasting 3 to 4 months. These newer treatments are highly effective, easier to finish, and carry a significantly lower risk of liver damage than older 9-month protocols.

If you have been diagnosed with Latent TB Infection (LTBI), it means you have TB bacteria in your body, but they are “asleep” and not currently making you sick [1]. The goal of treatment is to kill these dormant bacteria now so they can never “wake up” and cause active, contagious disease in the future [2][3].

Think of latent TB treatment as an “insurance policy” for your future health. While you feel fine now, certain life events—like aging, developing diabetes, or needing certain medications—could weaken your immune system and allow TB to become active [4][5].

Modern Short-Course Regimens

For decades, the standard treatment was a daily pill called isoniazid taken for 9 months. Today, medical guidelines have shifted toward much shorter, safer, and more effective “short-course” regimens [6][7]. These modern treatments use a class of drugs called rifamycins to kill the bacteria more efficiently.

Regimen Name Medications Duration Frequency Why it’s preferred
3HP Isoniazid + Rifapentine 3 Months Once Weekly Highest completion rates; very convenient [8].
4R Rifampin 4 Months Daily Safer for the liver than isoniazid alone [9].
3HR Isoniazid + Rifampin 3 Months Daily Common for children and in some global settings [10].

Why Shorter is Better

Research has shown that patients are much more likely to finish a 3- or 4-month course than a 9-month one [8][6]. Finishing the entire course is the only way to ensure all the dormant bacteria are gone.

Beyond convenience, these shorter regimens are generally safer for your liver. Isoniazid-only treatment for 9 months carries a higher risk of hepatotoxicity (liver damage) compared to the newer rifamycin-based short courses [10][11].

Crucial Safety Warning: The “Orange Fluid” Effect

If you are taking a rifamycin (such as Rifampin or Rifapentine), you will likely experience a completely harmless, yet terrifying side effect if you are not prepared: your urine, sweat, tears, and saliva may turn bright orange or red [12].

This is a normal, expected reaction to the medication. It does not mean you are bleeding internally, and it does not mean your liver is failing. However, you should avoid wearing soft contact lenses while on these drugs, as the orange tears can permanently stain them.

Liver Health and Monitoring

While harmless orange urine is expected, actual liver stress requires medical attention.

  • Liver Health: You may have blood tests (AST/ALT) to check your liver function before and during treatment [13].
  • Dangerous Signs to Watch For: In contrast to bright orange urine, if you experience dark “tea-colored” or brown urine, yellowing of the eyes or skin (jaundice), persistent nausea, or pain in the upper right side of your stomach, contact your doctor immediately [14].
  • Alcohol Warning: Alcohol significantly increases the risk of liver damage when combined with TB medications. Do not drink alcohol while you are completing your treatment [15].
  • Drug Interactions: Rifamycins can make other medications significantly less effective, particularly birth control pills and blood thinners [16]. You must discuss alternative birth control methods with your provider.
  • Flu-like Symptoms: Some people on the once-weekly 3HP regimen may feel achy or feverish for a day after their dose; report this “systemic reaction” to your provider [17][18].

Treatment for latent TB is a proactive step toward a healthier life. By choosing a short-course regimen, you can protect yourself with less time and lower risk [19][20].

Return to Understanding Your TB Diagnosis

Common questions in this guide

What are the best treatment options for latent TB?
Modern treatment for latent TB relies on short-course regimens lasting 3 to 4 months. These include once-weekly combinations like 3HP or daily medications like 4R, which are faster and safer than older 9-month treatments.
Why do latent TB medications turn urine orange?
Medications called rifamycins, such as Rifampin and Rifapentine, naturally cause bodily fluids like urine, sweat, and tears to turn bright orange or red. This is a normal, harmless side effect and does not mean you are bleeding or experiencing liver failure.
Can I drink alcohol while taking latent TB medication?
No, you should not drink alcohol during your latent TB treatment. Combining alcohol with these medications significantly increases your risk of developing severe liver damage.
What signs of liver damage should I watch for during TB treatment?
Contact your doctor immediately if you develop dark tea-colored urine, yellowing of your eyes or skin, persistent nausea, or pain in your upper right stomach. These can be warning signs of liver stress or damage.
Will latent TB medications interfere with my birth control?
Yes, rifamycin-based medications can make birth control pills and certain other medications less effective. You will need to discuss alternative methods of contraception with your healthcare provider while undergoing treatment.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which short-course regimen do you recommend for me: the once-weekly (3HP) or the daily (4R) option?
  2. 2.How often will we need to check my liver enzymes (AST/ALT) while I am on these medications?
  3. 3.Will these medications interact with any of my current prescriptions, such as birth control or vitamins?
  4. 4.What specific signs of a drug reaction or liver stress should I watch for at home?
  5. 5.If I miss a dose of the once-weekly medication, how should I get back on track?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    The definition of tuberculosis infection based on the spectrum of tuberculosis disease.

    Migliori GB, Ong CWM, Petrone L, et al.

    Breathe (Sheffield, England) 2021; (17(3)):210079 doi:10.1183/20734735.0079-2021.

    PMID: 35035549
  2. 2

    Anatomic and Cellular Niches for Mycobacterium tuberculosis in Latent Tuberculosis Infection.

    Mayito J, Andia I, Belay M, et al.

    The Journal of infectious diseases 2019; (219(5)):685-694 doi:10.1093/infdis/jiy579.

    PMID: 30376080
  3. 3

    Latent Tuberculosis Infection among Household Contacts of Drug-sensitive Pulmonary Tuberculosis Patients: A Cross-sectional Study from Medan, Indonesia.

    Sinaga BYM, Siregar J, Sormin DE, et al.

    Acta medica Philippina 2025; (59(19)):84-90 doi:10.47895/amp.vi0.10048.

    PMID: 41531702
  4. 4

    Investigation of the prevalence of latent tuberculosis in cancer patients compared to non-cancer patients: a case-control study.

    Mortezazadeh M, Karimi M, Esfandbod M, et al.

    Oncology reviews 2024; (18()):1445678 doi:10.3389/or.2024.1445678.

    PMID: 39697587
  5. 5

    Latent and Active Tuberculosis Infection Increase Immune Activation in Individuals Co-Infected with HIV.

    Sullivan ZA, Wong EB, Ndung'u T, et al.

    EBioMedicine 2015; (2(4)):334-340 doi:10.1016/j.ebiom.2015.03.005.

    PMID: 26114158
  6. 6

    Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis.

    Tseng SY, Huang YS, Chang TE, et al.

    Journal of the Chinese Medical Association : JCMA 2021; (84(11)):993-1000 doi:10.1097/JCMA.0000000000000605.

    PMID: 34747900
  7. 7

    Adverse events of tuberculosis preventive therapy among individuals with latent tuberculosis infection: A nationwide cohort study in South Korea.

    Oh SH, Lee J, Jo J, Kwon JW

    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2025; (156()):107914 doi:10.1016/j.ijid.2025.107914.

    PMID: 40288747
  8. 8

    Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis.

    Njie GJ, Morris SB, Woodruff RY, et al.

    American journal of preventive medicine 2018; (55(2)):244-252 doi:10.1016/j.amepre.2018.04.030.

    PMID: 29910114
  9. 9

    Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs.

    Ronald LA, FitzGerald JM, Bartlett-Esquilant G, et al.

    The European respiratory journal 2020; (55(3)) doi:10.1183/13993003.02048-2019.

    PMID: 31980498
  10. 10

    Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan.

    Sun HY, Huang YW, Huang WC, et al.

    Tuberculosis (Edinburgh, Scotland) 2018; (111()):121-126 doi:10.1016/j.tube.2018.05.013.

    PMID: 30029896
  11. 11

    Completion Rates, Adverse Effects, and Costs of a 3-Month and 9-Month Treatment Regimen for Latent Tuberculosis Infection in California Inmates, 2011-2014.

    Wheeler C, Mohle-Boetani J

    Public health reports (Washington, D.C. : 1974) 2019; (134(1_suppl)):71S-79S doi:10.1177/0033354919826557.

    PMID: 31059418
  12. 12

    Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different Settings.

    Bastos ML, Campbell JR, Oxlade O, et al.

    Annals of internal medicine 2020; (173(3)):169-178 doi:10.7326/M19-3741.

    PMID: 32539440
  13. 13

    Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.

    Bliven-Sizemore EE, Sterling TR, Shang N, et al.

    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2015; (19(9)):1039-44, i-v doi:10.5588/ijtld.14.0829.

    PMID: 26260821
  14. 14

    Behçet's disease with latent Mycobacterium tuberculosis infection.

    Shen Y, Ma H, Luo D, et al.

    Open medicine (Warsaw, Poland) 2021; (16(1)):14-22 doi:10.1515/med-2021-0002.

    PMID: 33336078
  15. 15

    Impacts of hepatitis B and hepatitis C co-infection with tuberculosis, a prospective cohort study.

    Feleke BE, Feleke TE, Adane WG, Girma A

    Virology journal 2020; (17(1)):113 doi:10.1186/s12985-020-01385-z.

    PMID: 32703225
  16. 16

    Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial.

    Dooley KE, Savic R, Gupte A, et al.

    The lancet. HIV 2020; (7(6)):e401-e409 doi:10.1016/S2352-3018(20)30032-1.

    PMID: 32240629
  17. 17

    Impact of Age on Outcome of Rifapentine-Based Weekly Therapy for Latent Tuberculosis Infection.

    Huang HL, Lee MR, Cheng MH, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021; (73(5)):e1064-e1071 doi:10.1093/cid/ciaa1741.

    PMID: 33215187
  18. 18

    Isoniazid Concentration and NAT2 Genotype Predict Risk of Systemic Drug Reactions during 3HP for LTBI.

    Lee MR, Huang HL, Lin SW, et al.

    Journal of clinical medicine 2019; (8(6)) doi:10.3390/jcm8060812.

    PMID: 31174321
  19. 19

    Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection.

    Gray EL, Goldberg HF

    Internal medicine journal 2016; (46(3)):281-7 doi:10.1111/imj.12979.

    PMID: 26648478
  20. 20

    Rifapentine for the treatment of latent tuberculosis.

    Egelund EF, Peloquin CA

    Expert review of clinical pharmacology 2016; (9(10)):1253-1261 doi:10.1080/17512433.2016.1222270.

    PMID: 27545595

This page provides educational information about Latent TB Infection treatments. Always consult your healthcare provider or infectious disease specialist before starting or changing any medication regimen.

Get notified when new evidence is published on Tuberculosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.